Clinical trial
A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501…
NCT00090220 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00090220 |
|---|---|
| Title | A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) |
| Official title | Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Healthy Adult Female Participants, Prevention, Papillomavirus Infection, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 |
| Intervention type | Biological |
| Interventions | Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, Comparator: Placebo |
| Enrollment | 3,819 |
| Start date | Jun 16, 2004 |
| Primary completion | May 21, 2009 |
| Completion | Nov 12, 2015 |
| First posted | Aug 27, 2004 |
| Last update posted | Apr 21, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: